Pediatric gastrointestinal stromal tumor

Seminars in Pediatric Surgery

Volumn 21, Issue 1, 2012, Pages 31-43

  Janeway, Katherine A ^a   Weldon, Christopher B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Gastrointestinal stromal tumor; GIST; Pediatric; Review

Indexed keywords

B RAF KINASE; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; SUNITINIB;

ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CARCINOGENESIS; CARNEY COMPLEX; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GERM LINE; HUMAN; MINIMALLY INVASIVE SURGERY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMATIC MUTATION;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; YOUNG ADULT;

EID: 84855874473     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2011.10.003     Document Type: Article

References (103)

1. Pappo A.S., Janeway K.A. Pediatric gastrointestinal stromal tumors. Hematol/Oncol Clin North Am 2009, 23:15-34. vii.
2. Cypriano M.S., Jenkins J.J., Pappo A.S., et al. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 2004, 101:39-50.
3. Price V.E., Zielenska M., Chilton-MacNeill S., et al. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer 2005, 45:20-24.
4. Miettinen M., Lasota J., Sobin L.H. Gastrointestinal stromal tumors of the stomach in children and young adults: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005, 29:1373-1381.
5. Agaram N.P., Laquaglia M.P., Ustun B., et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008, 14:3204-3215.
6. Benesch M., Leuschner I., Wardelmann E., et al. Gastrointestinal stromal tumours in children and young adults: A clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS). Eur J Cancer 2011, 47:1692-1698.
7. Kerr J.Z., Hicks M.J., Nuchtern J.G., et al. Gastrointestinal autonomic nerve tumors in the pediatric population: A report of four cases and a review of the literature. Cancer 1999, 85:220-230.
8. Otto C., Agaimy A., Braun A., et al. Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: A comparative clinical and histomorphological study of three cases including a new case of Carney triad. Diagn. Pathologe 2011, 6:52.
9. Chaudhry U.I., DeMatteo R.P. Management of resectable gastrointestinal stromal tumor. Hematol/Oncol Clin North Am 2009, 23:79-96. viii.
10. Nilsson B., Bümming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors. The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-A population-based study in western Sweden. Cancer 2005, 103:821-829.
11. Scarpa M., Bertin M., Ruffolo C., et al. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol 2008, 98:384-392.
12. Benesch M., Wardelmann E., Ferrari A., et al. Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatr Blood Cancer 2009, 53:1171-1179.
13. Kaemmer D.A., Otto J., Lassay L., et al. The Gist of literature on pediatric GIST: Review of clinical presentation. J Pediatr Hematol/Oncol 2009, 31:108-112.
14. Pisters P.W., Patel S.R. Gastrointestinal stromal tumors: Current management. J Surg Oncol 2010, 102:530-538.
15. Carney J.A. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): Natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999, 74:543-552.
16. McWhinney S.R., Pasini B., Stratakis C.A. International Carney Triad and Carney-Stratakis Syndrome Consortium. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 2007, 357:1054-1056.
17. Pasini B., McWhinney S.R., Bei T., et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008, 16:79-88.
18. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
19. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
20. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47:853-859.
21. Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22:3813-3825.
22. Hostein I., Faur N., Primois C., et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010, 133:141-148.
23. Janeway K.A., Liegl B., Harlow A., et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007, 67:9084-9088.
24. Janeway K.A., Kim S.Y., Lodish M., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011, 108:314-318.
25. Gottlieb E., Tomlinson I.P. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer 2005, 5:857-866.
26. van Nederveen F.H., Gaal J., et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: A retrospective and prospective analysis. Lancet Oncol 2009, 10:764-771.
27. Bardella C., Pollard P.J., Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta 2011 1807, 11:1432-1443.
28. Burnichon N., Brière J.J., Libé R., et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010, 19:3011-3020.
29. Pantaleo M.A., Astolfi A., Indio V., et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 2011, 103:983-987.
30. Rege T.A., Wagner A.J., Corless C.L., et al. "Pediatric-type" gastrointestinal stromal tumors in adults: Distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol 2011, 35:495-504.
31. Brenner D., Elliston C., Hall E., et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001, 176:289-296.
32. Blackstein M.E., Blay J.Y., Corless C., et al. Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Can J Gastroenterol 2006, 20:157-163.
33. Casali P.G., Jost L., Reichardt P., et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):64-67.
34. Demetri G.D., Benjamin R.S., Blanke C.D., et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST)-Update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw 2007, 5(Suppl 2):S1-S29. quiz: S30.
35. Blay J.Y., von Mehren M., Blackstein M.E. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010, 116:5126-5137.
36. Sepe P.S., Brugge W.R. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat. Rev Gastroenterol Hepatol 2009, 6:363-371.
37. Hedenbro J.L., Ekelund M., Wetterberg P. Endoscopic diagnosis of submucosal gastric lesions. The results after routine endoscopy. Surg Endosc 1991, 5:20-23.
38. Hwang J.H., Saunders M.D., Rulyak S.J., et al. A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial masses. Gastrointest Endosc 2005, 62:202-208.
39. Brand B., Oesterhelweg L., Binmoeller K.F., et al. Impact of endoscopic ultrasound for evaluation of submucosal lesions in gastrointestinal tract. Dig Liver Dis 2002, 34:290-297.
40. Hunt G.C., Rader A.E., Faigel D.O. A comparison of EUS features between CD-117 positive GI stromal tumors and CD-117 negative GI spindle cell tumors. Gastrointest Endosc 2003, 57:469-474.
41. Polkowski M. Endoscopic ultrasound and endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of malignant submucosal tumors. Endoscopy 2005, 37:635-645.
42. Gress F., Schmitt C., Savides T., et al. Interobserver agreement for EUS in the evaluation and diagnosis of submucosal masses. Gastrointest Endosc 2001, 53:71-76.
43. Chak A., Canto M.I., Rösch T., et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc 1997, 45:468-473.
44. Palazzo L., Landi B., Cellier C., et al. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut 2000, 46:88-92.
45. Lautz T.B., Raval M.V., Reynolds M., et al. Adhesive small bowel obstruction in children and adolescents: Operative utilization and factors associated with bowel loss. J Am Coll Surg 2011, 212:855-861.
46. Hohenberger P., Ronellenfitsch U., Oladeji O., et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010, 97:1854-1859.
47. Cantor M.J., Davila R.E., Faigel D.O. Yield of tissue sampling for subepithelial lesions evaluated by EUS: A comparison between forceps biopsies and endoscopic submucosal resection. Gastrointest Endosc 2006, 64:29-34.
48. Hunt G.C., Smith P.P., Faigel D.O. Yield of tissue sampling for submucosal lesions evaluated by EUS. Gastrointest Endosc 2003, 57:68-72.
49. Hwang J.H., Rulyak S.D., Kimmey M.B. American Gastroenterological Association Institute. American Gastroenterological Association Institute technical review on the management of gastric subepithelial masses. Gastroenterology 2006, 130:2217-2228.
50. Akahoshi K., Sumida Y., Matsui N., et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. World J Gastroenterol 2007, 13:2077-2082.
51. Ando N., Goto H., Niwa Y., et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002, 55:37-43.
52. Chhieng D.C., Jhala D., Jhala N., et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy: A study of 103 cases. Cancer 2002, 96:232-239.
53. Giovannini M., Seitz J.F., Monges G., et al. Fine-needle aspiration cytology guided by endoscopic ultrasonography: Results in 141 patients. Endoscopy 1995, 27:171-177.
54. Vander Noot M.R., Eloubeidi M.A., Chen V.K., et al. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 2004, 102:157-163.
55. Wiersema M.J., Wiersema L.M., Khusro Q., et al. Combined endosonography and fine-needle aspiration cytology in the evaluation of gastrointestinal lesions. Gastrointest Endosc 1994, 40:199-206.
56. Williams D.B., Sahai A.V., Aabakken L., et al. Endoscopic ultrasound guided fine needle aspiration biopsy: A large single centre experience. Gut 1999, 44:720-726.
57. Klapman J.B., Logrono R., Dye C.E., et al. Clinical impact of on-site cytopathology interpretation on endoscopic ultrasound-guided fine needle aspiration. Am J Gastroenterol 2003, 98:1289-1294.
58. Levy M.J., Jondal M.L., Clain J., et al. Preliminary experience with an EUS-guided trucut biopsy needle compared with EUS-guided FNA. Gastrointest Endosc 2003, 57:101-106.
59. Levy M.J., Wiersema M.J. EUS-guided trucut biopsy. Gastrointest Endosc 2005, 62:417-426.
60. Mazur M.T., Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507-519.
61. Lee J.R., Joshi V., Griffin J.W., et al. Gastrointestinal autonomic nerve tumor: Immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001, 25:979-987.
62. Miettinen M., Sobin L.H., Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000, 13:1134-1142.
63. Demetri G.D., von Mehren M., Antonescu C.R., et al. NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw 2010, 8(Suppl 2):S1-S41. quiz: S2-4.
64. Rossi C.R., Mocellin S., Mencarelli R., et al. Gastrointestinal stromal tumors: From a surgical to a molecular approach. Int J Cancer 2003, 107:171-176.
65. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
66. Langer C., Gunawan B., Schüler P., et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003, 90:332-339.
67. An J.Y., Choi M.G., Noh J.H., et al. Gastric GIST: A single institutional retrospective experience with surgical treatment for primary disease. Eur J Surg Oncol 2007, 33:1030-1035.
68. Crosby J.A., Catton C.N., Davis A., et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001, 8:50-59.
69. Tryggvason G., Kristmundsson T., Orvar K., et al. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990-2003. Dig Dis Sci 2007, 52:2249-2253.
70. Nishimura J., Nakajima K., Omori T., et al. Surgical strategy for gastric gastrointestinal stromal tumors. Laparoscopic vs. open resection. Surg Endosc 2007, 21:875-878.
71. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566-578.
72. Raut C.P., Ashley S.W. How I do it: Surgical management of gastrointestinal stromal tumors. J Gastrointest Surg 2008, 12:1592-1599.
73. Rutkowski P., Nowecki Z.I., Michej W., et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007, 14:2018-2027.
74. Otani Y., Furukawa T., Yoshida M., et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006, 139:484-492.
75. Novitsky Y.W., Kercher K.W., Sing R.F., et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006, 243:738-745. discussion: 45-7.
76. Bucher P., Egger J.F., Gervaz P., et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2006, 32:310-314.
77. Dematteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
78. Corless C.L., Ballman K.V., Antonescu C., et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal tumor (GIST): Results of the intergroup phase III trial ACOSOG. J Clin Oncol 2010, Z9001:28. Abstract 10006.
79. Heinrich M.C., Maki R.G., Corless C.L., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26:5352-5359.
80. Barr R.D. Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer 2010, 55:18-25.
81. Joensuu H., Eriksson M., Hatrmann K., et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 2011, 29(suppl). abstract LBA1.
82. Gold J.S., van der Zwan S.M., Gonen M., et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007, 14:134-142.
83. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006, 24:2325-2331.
84. Bonvalot S., Eldweny H., Pechoux C.L., et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006, 13:1596-1603.
85. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007, 245:347-352.
86. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007, 245:341-346.
87. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
88. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase, vol S0033. J Clin Oncol 2008, 26:626-632.
89. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103.
90. Heinrich M.C., Owzar K., Corless C.L., et al. Correlation of kinase genotype and clinical outcome in the North American InterGroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008, 26:5360-5367.
91. Hayashi Y., Okazaki T., Yamataka A., et al. Gastrointestinal stromal tumor in a child and review of the literature. Pediatr Surg Int 2005, 21:914-917.
92. Janeway K.A., Albritton K.H., Van Den Abbeele A.D., et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009, 52:767-771.
93. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368:1329-1338.
94. Demetri G.D. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011, 38(Suppl 1):S10-S19.
95. Le Cesne A., Blay J.Y., Bui B.N., et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010, 46:1344-1351.
96. Montemurro M., Schöffski P., Reichardt P., et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009, 45:2293-2297.
97. Bond M., Bernstein M.L., Pappo A., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's Oncology Group study. Pediatr Blood Cancer 2008, 50:254-258.
98. Dubois S.G., Shusterman S., Ingle A.M., et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A children's oncology group study. Clin Cancer Res 2011, 17:5113-5122.
99. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
100. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
101. Chien C.H., Chien R.N., Yen C.L., et al. The role of endoscopic ultrasonography examination for evaluation and surveillance of gastric subepithelial masses. Chang Gung Med J 2010, 33:73-81.
102. Lok K.H., Lai L., Yiu H.L., et al. Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria. J Gastrointest Liver Dis 2009, 18:177-180.
103. Melzer E., Fidder H. The natural course of upper gastrointestinal submucosal tumors: An endoscopic ultrasound survey. Isr Med Assoc J 2000, 2:430-432.